



"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EV332944755US
DATE OF DEPOSIT November 10, 2003

Attorney Docket No. P31828C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Stephen Alistair Smith November 10, 2003
Serial No.: Not Yet Assigned Group Art Unit No.: Not Yet Assigned
Filed: Herewith Examiner: Not Yet Assigned
For: TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND
SULPHONYLUREA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\kls\cases\p31828c3\IDS Letter.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		FILING DATE Herewith	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Avandia Drug Profile. <i>PDR Health Website</i> – www.pdrhealth.com
	Weinstock, et al. <i>Int'l. J. Exp. Clin. Pharmacol.</i> , <u>54</u> : 169-178 (1997).
	Iwamoto, et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled By Sulphonylurea Therapy Alone". <i>Diabetic Medicine</i> , <u>13</u> : 365-370 (1995).
	Alberti, et al., "A Desktop Guide for the Management of Non-Insulin Dependent Diabetes Mellitus (NIDDM): An Update". <i>Diabetic Medicine</i> , <u>11</u> : 899-909 (1994).
	Iwamoto. "Usage of New Oral Anti-Diabetic Drugs". <i>Klinika</i> , <u>22(6)</u> pp. 445-450 (1995).
	Nakano, et al., "Clinical Evaluation of a New Oral Hypoglycemic Drug, CS-045, on Daily Profile of Blood Glucose in Patients with Non-Insulin Dependent Diabetes Mellitus". <i>Rinsyou Iyaku (Clinical Medicine)</i> , <u>9th Vol., Supp. 3</u> : pp. 151-164 (1993).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P31828C3PRED. SERIAL NO.
10/103,326**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*APPLICANT
Stephen Alistair SmithPRED. FILING DATE
March 21, 2002GROUP
Not Yet Assigned**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,965,584	10/1999	Ikeda, et al.	514	342	
	US20020016287	2/7/02	Buckingham, et al.	514	3	
	US20020177612	11/28/02	Grannett, et al.	514	340	
	6,291,495	9/18/01	Rieveley	514	369	
	6,153,632	11/28/00	Rieveley	514	369	
	5,972,973	10/26/99	Whitcomb	514	342	
	5,859,037	1/12/99	Whitcomb	514	369	
	5,952,356	9/14/99	Ikeda, et al.	514	340	
	6,150,383	11/21/00	Ikeda, et al.	514	342	
	6,031,004	2/29/00	Timmins, et al.	514	635	
	4,985,862	1/23/90	Alessi, et al.	514	360	
	5,068,342	11/26/91	Zask, et al.	548	183	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 98/36755	8/1998	PCT				
	0 861 666	9/1998	EPO				
	WO 93/03724	3/1993	PCT				
	0 749 751	12/1996	EPO				
	0 306 228	3/1989	EPO				
	WO 99/03478	1/28/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Kelley, et al., "Troglitazone", <i>Current Opinion in Endocrinology and Diabetes</i> , <u>5(2)</u> : 90-96 (1998) (XP002080820).
	Scheen, et al., "Oral Antidiabetic Agents, A Guide to Selection", <i>Disease Management</i> , <u>55(2)</u> : 225-236 (XP002080821).
	Scheen et al., "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Achievements and Future Developments". <i>Drugs</i> , <u>54(3)</u> : 355-368 (1997) (XP002080822).
	Iwatamoto, et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone". <i>Diabetic Medicine</i> , <u>13(4)</u> : 365-370 (1996) (XP002064289).
	Gareth Williams. "Management of Non-Insulin-Dependent Diabetes Mellitus", <i>The Lancet</i> , <u>343</u> : 95-100 (1994).
	Kuzuya, et al., "A Pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus". <i>Diabetes Research & Clinical Practice</i> , <u>11</u> : 147-154 (1991).
	Lehmann, et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPAR γ)". <i>J. Biol. Chem.</i> , <u>270(22)</u> : 12953-12956 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,900,435	5/4/99	Martin D. Meglasson	514	565	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 97/17975	5/22/97	PCT				
	WO 95/21608	8/1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Donnelly, et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and new Pharmacological Approaches to Metabolism". <i>Br. J. Clin. Pharmacol.</i> , <u>37</u> : 311-320 (1994).
	Jackson, et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes". <i>Diabetes</i> , <u>36</u> : 632-640 (1987).
	Hofmann, et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers". <i>Diabetes Care</i> , <u>15</u> (8): 1075-1078 (1992).
	Foot, et al., "Improved Metabolic Control by Addition of Troglitazone to Glibenclamide Therapy in Non-Insulin Dependent Diabetics". <i>Diabetologia</i> , <u>38</u> (S1): A44 (1995).
	Whitcomb, et al., "Thiazolidinediones". <i>Exp. Opin. Invest. Drugs</i> , <u>4</u> (12): 1299-1309 (1995).
	Leif C. Groop, "Sulfonylureas in NIDDM". <i>Diabetes Care</i> , <u>15</u> (6): 737-754 (1992).
	Vialettes, et al., "Pharmacological Approach in the Treatment of Insulin Resistance". <i>Horm. Res.</i> , <u>38</u> : 51-56 (1992).
	Sohda, et al., "Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its Derivatives". <i>Chem. Pharm. Bull.</i> , <u>30</u> (10): 3580-3600 (1982).
	Harold E. Lebovitz, "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". <i>Diabetes Care</i> , <u>17</u> (12): 1542-1544 (1994).
	Iwamoto, et al., "effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM". <i>Diabetes Care</i> , <u>14</u> (11): 1083-1086 (1991).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Hotta. <i>Tonyobyu</i> , <u>Update 10</u> , pp. 68-77, April 1994 (with translation).
	Hotta. <i>Chronic Disease</i> , <u>6(1)</u> . January 5, 1995.
	Ishida, et al., "Oral Hypoglycemic Agents - New Oral Drugs and New Strategy of Treatment". <i>Clinic All-Round</i> , <u>43</u> : 2615-2621 (1994).
	Cusi, et al., "Metformin: A Review of its Metabolic Effects". <i>Diabetes Review</i> , <u>6(2)</u> : 89-131 (1998).
	Arshag D. Mooradian. "Drug Therapy of Non-Insulin-Dependent Diabetes Mellitus in the Elderly". <i>Drugs</i> , <u>51(6)</u> : 931-941 (1996).
	Windholz, et al., <i>The Merck Index</i> , 10th Edition, pp. 635. Abstract Nos. 4300 & 4302 (1983).
	K. Doi, "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Development". <i>J. Japan Diabetes Science</i> , <u>3(Supp. 1)</u> : 962-973 (1990).
	Kramer, et al., "Differential Interaction of Glimepiride and Glibenclamide with the Beta-Cell Sulfonylurea Receptor 2 Photoaffinity-Labeling of a 65 KDA Protein by H-3 Glimepiride. <i>Biochim. et Biophys. Acta-Biomembranes</i> , <u>1191(2)</u> : 270-290 (1994).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	